Drug search by name

Kisqali Femara Co-Pack and Cholesterol

Result of checking the interaction of drug Kisqali Femara Co-Pack and disease Cholesterol for safety when used together.

Check result:

Kisqali Femara Co-Pack <> Cholesterol

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

In an adjuvant clinical trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients. CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients. Also in the adjuvant setting, an increase of >=1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%). Caution is recommended when prescribing letrozole to these patients. Consideration should be given to monitoring serum cholesterol.

Kisqali Femara Co-Pack

Generic Name: letrozole / ribociclib

Brand Name: Kisqali Femara Co-Pack 200 mg-25 mg Dose, Kisqali Femara Co-Pack 400 mg-25 mg Dose, Kisqali Femara Co-Pack 600 mg-25 mg Dose

Synonyms: Kisqali Femara Co-Pack 200 mg-2.5 mg Dose

What is Kisqali Femara Co-Pack?